Search
Fosun Pharma Announces FDA Approval for Subsidiary Henlius Biotech's Denosumab Injection
2025-09-01 /
Read about 0 minute
Author：小编
Fosun Pharma's subsidiary, Henlius Biotech, has recently secured approval from the U.S. Food and Drug Administration (FDA) for its proprietary denosumab injection, HLX14, available in two concentrations: 60mg/mL and 120mg/1.7mL. This medication is designed to treat osteoporosis and related conditions in postmenopausal women at heightened risk of fractures, particularly those with glucocorticoid-induced osteoporosis. Furthermore, marketing applications for HLX14 have been submitted to regulatory bodies such as the European Medicines Agency and Health Canada.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
